Thea Supplement: Use of Intracameral Cefuroxime
In 2007, results from the ESCRS Endophthalmitis Prophylaxis Study showed that intracameral cefuroxime significantly reduced the risk of endophthalmitis after cataract surgery [ESCRS Endophthalmitis Study Group. J Cataract Refract. Surg. 2007;33:978-988]. Then in 2012, a major obstacle to systematic intracameral use was eliminated when Aprokam® (cefuroxime 50mg powder for injection; Laboratoires Théa) was approved across Europe as the first and only product indicated for intracameral administration to prevent endophthalmitis after cataract surgery. As of September, 2014, this single-use agent is available in 23 European countries, with approval being sought elsewhere around the world.
Download Supplement
Tags: endophthalmitis
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.